본문 바로가기
KERD
논문KCI 등재

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

Jia-Horng Kao|Chih-Lin Lin
대한간학회 (The korean Association for the Study of the Liver)|2023.07|Clinical and Molecular Hepatology|제29권 제3호|pp. 605-622

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Hepatocellular carcinomaChronic hepatitis BCirrhosis

초록

Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC) in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors are involved in HBV-related hepatocarcinogenesis. Hepatitis B viral load is the most important risk factor of HCC development. In addition, HBV integration, HBV genotype C, and core-promoter mutations are also associated with a risk of HCC development. For untreated chronic hepatitis B (CHB) patients, the estimated HCC incidence rates per 100 patient-years were 0.03–0.17 in inactive carriers, 0.07–0.42 in asymptomatic carriers, 0.12–0.49 in chronic hepatitis, and 2.03–3.37 in cirrhosis. Complementary to HBV DNA, serum levels of the hepatitis B surface antigen and hepatitis B core-related antigen (HBcrAg) can predict the occurrence of HCC for untreated patients with low and intermediate viral loads, respectively. For patients receiving antiviral therapy, the risks of HCC occurrence 40–60% lower than those for untreated patients. Patients treated with residual detectable HBV DNA or intrahepatic cccDNA still have a risk of HCC. Serum levels of HBcrAg, M2BPGi and fibrosis-4 are predictive of the risk of HCC development in treated patients. Several well-developed HCC risk scores can help clinicians identify high-risk CHB patients for HCC surveillance, regardless of treatment status. These strategies can help minimize the threat of HCC and prolong survival in CHB patients.

Abstract

Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC) in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors are involved in HBV-related hepatocarcinogenesis. Hepatitis B viral load is the most important risk factor of HCC development. In addition, HBV integration, HBV genotype C, and core-promoter mutations are also associated with a risk of HCC development. For untreated chronic hepatitis B (CHB) patients, the estimated HCC incidence rates per 100 patient-years were 0.03–0.17 in inactive carriers, 0.07–0.42 in asymptomatic carriers, 0.12–0.49 in chronic hepatitis, and 2.03–3.37 in cirrhosis. Complementary to HBV DNA, serum levels of the hepatitis B surface antigen and hepatitis B core-related antigen (HBcrAg) can predict the occurrence of HCC for untreated patients with low and intermediate viral loads, respectively. For patients receiving antiviral therapy, the risks of HCC occurrence 40–60% lower than those for untreated patients. Patients treated with residual detectable HBV DNA or intrahepatic cccDNA still have a risk of HCC. Serum levels of HBcrAg, M2BPGi and fibrosis-4 are predictive of the risk of HCC development in treated patients. Several well-developed HCC risk scores can help clinicians identify high-risk CHB patients for HCC surveillance, regardless of treatment status. These strategies can help minimize the threat of HCC and prolong survival in CHB patients.

참고문헌 (141)

  1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
  2. Yang JD, "A global view of hepatocellular carcinoma : trends, risk, prevention and management", Nat Rev Gastroenterol Hepatol, 16, pp.589~604 (2019)
  3. Kao JH, "Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma : epidemiologic and molecular biological aspects", Adv Cancer Res, 108, pp.21~72 (2010)
  4. "Hepatitis B"[URL]
  5. "Global hepatitis report, 2017"[URL]
  6. Lin CL, "Hepatitis B : Immunization and impact on natural history and cancer incidence", Gastroenterol Clin North Am, 49, pp.201~214 (2020)
  7. Chang KC, "Universal infant hepatitis B virus(HBV)vaccination for 35 years : Moving toward the eradication of HBV", J Infect Dis, 225, pp.431~435 (2022)
  8. Chen CL, "Slow decline of hepatitis B burden in general population : Results from a population-based survey and longitudinal follow-up study in Taiwan", J Hepatol, 63, pp.354~363 (2015)
  9. Kao JH, "Global control of hepatitis B virus infection", Lancet Infect Dis, 2, pp.395~403 (2002)
  10. Yuen MF, "Hepatitis B virus infection", Nat Rev Dis Primers, 4, pp.18035~ (2018)
  11. Raza SA, "Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma : a systematic review", Br J Cancer, 96, pp.1127~1134 (2007)
  12. Lin CL, "Review article : the prevention of hepatitis Brelated hepatocellular carcinoma", Aliment Pharmacol Ther, 48, pp.5~14 (2018)
  13. Kao JH, "Role of viral factors in the natural course and therapy of chronic hepatitis B", Hepatol Int, 1, pp.415~430 (2007)
  14. Lin CL, "Hepatitis B viral factors and clinical outcomes of chronic hepatitis B", J Biomed Sci, 15, pp.137~145 (2008)
  15. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
  16. Liu CJ, "Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers", J Infect Dis, 193, pp.1258~1265 (2006)
  17. Liu CJ, "Role of hepatitis B virus precore", core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma : a case-control study, 2006, pp.194, 594~599
  18. Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)
  19. Wong VW, "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers", J Clin Oncol, 28, pp.1660~1665 (2010)
  20. Buendia MA, "Hepatocellular carcinoma", Cold Spring Harb Perspect Med, 5, pp.a021444~ (2015)
  21. Kim GA, "Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients", Aliment Pharmacol Ther, 51, pp.1169~1179 (2020)
  22. Zoulim F, "Reasons to consider earlier treatment of chronic HBV infections", Gut, 61, pp.333~336 (2012)
  23. Mason WS, "Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection", J Virol, 84, pp.8308~8315 (2010)
  24. Mason WS, "HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant", Gastroenterology, 151, pp.986~998 (2016)
  25. Xu C, "The liver of woodchucks chronically infected with the woodchuck hepatitis virus contains foci of virus core antigennegative hepatocytes with both altered and normal morphology", Virology, 359, pp.283~294 (2007)
  26. Liu J, "Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis", Hepatol Commun, 6, pp.855~866 (2022)
  27. Svicher V, "Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B", Gut, 70, pp.2337~2348 (2021)
  28. Levrero M, "Mechanisms of HBV-induced hepatocellular carcinoma", J Hepatol, 64(1 Suppl), pp.S84~S101 (2016)
  29. Saitta C, "Hepatitis B virus(HBV)DNA integration in patients with occult HBV infection and hepatocellular carcinoma", Liver Int, 35, pp.2311~2317 (2015)
  30. Pollicino T, "HBV-integration studies in the clinic : Role in the natural history of infection", Viruses, 13, pp.368~ (2021)
  31. Li CL, "Cell-free virus-host chimera DNA from hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer", Hepatology, 72, pp.2063~2076 (2020)
  32. Péneau C, "Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma", Gut, 71, pp.616~626 (2022)
  33. Wang SH, "Unique features of hepatitis B virusrelated hepatocellular carcinoma in pathogenesis and clinical significance", Cancers(Basel), 13, pp.2454~ (2021)
  34. Fako V, "Hepatitis B Virus and Liver Disease", pp.143~162 (2018), Springer Nature Singapore Pte Ltd
  35. Lin CL, "Hepatitis B virus genotypes and variants", Cold Spring Harb Perspect Med, 5, pp.a021436~ (2015)
  36. Tseng TC, "Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers", Gut, 64, pp.292~302 (2015)
  37. Yang HI, "REVEALHBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.1134~1143 (2008)
  38. Choi YM, "Naturally occurring hepatitis B virus mutations leading to endoplasmic reticulum stress and their contribution to the progression of hepatocellular carcinoma", Int J Mol Sci, 20, pp.597~ (2019)
  39. Liang YJ, "Clinical implications of HBV PreS", S mutations and the effects of PreS2 deletion on mitochondria, liver fibrosis, and cancer development, 2021, pp.74, 641~655
  40. Velkov S, "The global hepatitis B virus genotype distribution approximated from available genotyping data", Genes(Basel), 9, pp.495~ (2018)
  41. McMahon BJ, "HBV genotype : A significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC : The hepatitis B Alaska study", Hepatology, 74, pp.2965~2973 (2021)
  42. Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : Results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
  43. Wang SH, "Gender disparity in chronic hepatitis B : Mechanisms of sex hormones", J Gastroenterol Hepatol, 30, pp.1237~1245 (2015)
  44. Raffetti E, "Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B : a systematic review and meta-analysis", Liver Int, 36, pp.1239~1251 (2016)
  45. Yu MW, "Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B : A large cohort study", Gastroenterology, 153, pp.1006~1017 (2017)
  46. Chan AW, "Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B", J Gastroenterol Hepatol, 32, pp.667~676 (2017)
  47. Kim MN, "Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver", Aliment Pharmacol Ther, 55, pp.97~107 (2022)
  48. Zucman-Rossi J, "Genetic landscape and biomarkers of hepatocellular carcinoma", Gastroenterology, 149, pp.1226~1239 (2015)
  49. Nault JC, "Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis", Hepatology, 60, pp.1983~1992 (2014)
  50. Jiang DK, "Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma", Nat Genet, 45, pp.72~75 (2013)
  51. Huang DQ, "Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase", Clin Gastroenterol Hepatol, 20, pp.1803~1812 (2022)
  52. Chen JD, "Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death", Gastroenterology, 138, pp.1747~1754 (2010)
  53. Siegel RL, "Cancer Statistics, 2021", CA Cancer J Clin, 71, pp.7~33 (2021)
  54. Sinn DH, "Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load", Hepatology, 62, pp.694~701 (2015)
  55. Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149 (2012)
  56. Liu J, "Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression", Hepatology, 64, pp.381~389 (2016)
  57. Kimura T, "Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load", J Clin Microbiol, 40, pp.439~445 (2002)
  58. Lin CL, "New perspectives of biomarkers for the management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.423~431 (2016)
  59. Mak LY, "Review article : hepatitis B core-related antigen(HBcrAg) : an emerging marker for chronic hepatitis B virus infection", Aliment Pharmacol Ther, 47, pp.43~54 (2018)
  60. Tada T, "HBcrAg predicts hepatocellular carcinoma development : An analysis using time-dependent receiver operating characteristics", J Hepatol, 65, pp.48~56 (2016)
  61. Tseng TC, "High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load", Gastroenterology, 157, pp.1518~1529 (2019)
  62. Tseng TC, "Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase", Am J Gastroenterol, 117, pp.748~757 (2022)
  63. Cloherty G, "Serum hepatitis B virus RNA as a potential diagnostic biomarker during chronic hepatitis B virus infection", Clin Liver Dis(Hoboken), 13, pp.90~92 (2019)
  64. van Campenhout MJH, "Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment", Hepatology, 68, pp.839~847 (2018)
  65. Huang YW, "On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy", Antivir Ther, 20, pp.369~375 (2015)
  66. Luo H, "Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues", J Viral Hepat, 27, pp.323~328 (2020)
  67. Halgand B, "Hepatitis B virus pregenomic RNA in hepatocellular carcinoma : A nosological and prognostic determinant", Hepatology, 67, pp.86~96 (2018)
  68. Lin CL, "Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B", J Clin Gastroenterol, 49, pp.705~713 (2015)
  69. Tseng TC, "Fibrosis-4 index helps identify HBV carriers with the lowest risk of hepatocellular carcinoma", Am J Gastroenterol, 112, pp.1564~1574 (2017)
  70. Zou X, "Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection", Liver Int, 37, pp.35~44 (2017)
  71. Liu J, "Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in untreated chronic hepatitis B patients", Sci Rep, 7, pp.14352~ (2017)
  72. Kim SU, "Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development", Liver Int, 37, pp.879~887 (2017)
  73. Mak LY, "Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients", World J Gastroenterol, 25, pp.1398~1408 (2019)
  74. Lichtinghagen R, "The Enhanced Liver Fibrosis(ELF)score : normal values, influence factors and proposed cut-off values", J Hepatol, 59, pp.236~242 (2013)
  75. Fernandes FF, "Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients", J Clin Gastroenterol, 49, pp.235~241 (2015)
  76. Kim BK, "Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test", Hepatology, 60, pp.1911~1919 (2014)
  77. Gupta S, "Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis", Ann Intern Med, 139, pp.46~50 (2003)
  78. Carr BI, "Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States", Dig Dis Sci, 52, pp.776~782 (2007)
  79. Lok AS, "Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma", Gastroenterology, 138, pp.493~502 (2010)
  80. Feng H, "PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma", BMC Cancer, 21, pp.401~ (2021)
  81. Yi X, "Alpha-fetoprotein-L3 in hepatocellular carcinoma : a meta-analysis", Clin Chim Acta, 425, pp.212~220 (2013)
  82. Marrero JA, "Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma", Gastroenterology, 137, pp.110~118 (2009)
  83. Johnson PJ, "The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers", Cancer Epidemiol Biomarkers Prev, 23, pp.144~153 (2014)
  84. Yang JD, "GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score", Cancer Epidemiol Biomarkers Prev, 28, pp.531~538 (2019)
  85. Singal AG, "GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis", Hepatology, 75, pp.541~549 (2022)
  86. Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
  87. Lee MH, "Prediction models of longterm cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles", Hepatology, 58, pp.546~554 (2013)
  88. Yang HI, "Incorporating serum level of hepatitis B surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis", Clin Gastroenterol Hepatol, 14, pp.461~468 (2016)
  89. Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)
  90. Poh Z, "Realworld risk score for hepatocellular carcinoma(RWS-HCC) : a clinically practical risk predictor for HCC in chronic hepatitis B", Gut, 65, pp.887~888 (2016)
  91. 신동현, "A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels", Gut and Liver, 11(4), pp.528~534 (2017), 거트앤리버 소화기연관학회협의회
  92. Fan C, "A simple AGED score for risk classification of primary liver cancer : development and validation with long-term prospective HBsAgpositive cohorts in Qidong, China", Gut, 68, pp.948~949 (2019)
  93. Rattananukrom C, "Comparison between using hepatocellular carcinoma(HCC)risk scores and the HCC national guideline to identify high-risk chronic hepatitis B patients for HCC surveillance in Thailand", JGH Open, 6, pp.408~420 (2022)
  94. Abu-Amara M, "The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection", Gut, 65, pp.1347~1358 (2016)
  95. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
  96. European Association for the Study of the Liver, "EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
  97. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
  98. Sung JJ, "Meta-analysis : Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma", Aliment Pharmacol Ther, 28, pp.1067~1077 (2008)
  99. Yang YF, "Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma : a meta-analysis", J Viral Hepat, 16, pp.265~271 (2009)
  100. Wong GL, "Meta-analysis : reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B", Aliment Pharmacol Ther, 32, pp.1059~1068 (2010)
  101. Liang KH, "Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B", J Infect Dis, 213, pp.966~974 (2016)
  102. Ren P, "Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBVrelated hepatocellular carcinoma for chronic hepatitis B patients at high risk", Expert Opin Biol Ther, 18, pp.1085~1094 (2018)
  103. Liu K, "Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis", Aliment Pharmacol Ther, 50, pp.1037~1048 (2019)
  104. Nguyen MH, "Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-A propensity score-matched study", J Infect Dis, 219, pp.10~18 (2019)
  105. Hsu YC, "Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir", J Viral Hepat, 25, pp.543~551 (2018)
  106. Lee HW, "Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B", J Viral Hepat, 28, pp.1570~1578 (2021)
  107. Tseng CH, "Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.1039~1052 (2020)
  108. Dave S, "Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B : A systematic review and meta-analysis", Hepatology, 73, pp.68~78 (2021)
  109. Yuan BH, "Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients : an updated meta-analysis", J Gastroenterol Hepatol, 37, pp.782~794 (2022)
  110. Kim JH, "Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment", Hepatology, 66, pp.335~343 (2017)
  111. Burdette DL, "Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy", PLoS One, 17, pp.e0262516~ (2022)
  112. Testoni B, "Serum hepatitis B core-related antigen(HBcrAg)correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients", J Hepatol, 70, pp.615~625 (2019)
  113. Wang L, "Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients", J Clin Microbiol, 57, pp.e01303-18~ (2019)
  114. Cheung KS, "Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy", J Viral Hepat, 24, pp.654~661 (2017)
  115. Hosaka T, "Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues", Aliment Pharmacol Ther, 49, pp.457~471 (2019)
  116. Tseng TC, "Baseline Mac-2 binding protein glycosylation isomer level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy", Liver Cancer, 9, pp.207~220 (2020)
  117. Murata A, "On-treatment serum Mac-2 binding protein glycosylation isomer(M2BPGi)level and risk of hepatocellular carcinoma development in patients with chronic hepatitis B during nucleot(s)ide analogue therapy", Int J Mol Sci, 21, pp.2051~ (2020)
  118. Su TH, "Serum Mac-2-binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B-related cirrhosis", J Infect Dis, 221, pp.589~597 (2020)
  119. Tseng TC, "One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment", Hepatol Int, 15, pp.105~113 (2021)
  120. Wang HW, "On-treatment changes in FIB-4 and 1-year FIB-4 values help identify patients with chronic hepatitis B receiving entecavir therapy who have the lowest risk of hepatocellular carcinoma", Cancers(Basel), 12, pp.1177~ (2020)
  121. Choi WM, "Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B", J Clin Invest, 132, pp.e154833~ (2022)
  122. Papatheodoridis G, "PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy", J Hepatol, 64, pp.800~806 (2016)
  123. Kim JH, "Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy", J Hepatol, 69, pp.1066~1073 (2018)
  124. 손원, "Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B", Clinical and Molecular Hepatology, 23(2), pp.170~178 (2017), 대한간학회[DOI]
  125. Chen CH, "Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir", Oncotarget, 8, pp.92431~92441 (2017)
  126. Hsu YC, "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B", J Hepatol, 69, pp.278~285 (2018)
  127. Yu JH, "Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir", tenofovir, 2019, pp.31, 865~872
  128. Yang HI, "Real-World effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B Patients treated with oral antiviral therapy", J Infect Dis, 221, pp.389~399 (2020)
  129. Brouwer WP, "Prediction of long-term clinical outcome in a diverse chronic hepatitis B population : Role of the PAGE-B score", J Viral Hepat, 24, pp.1023~1031 (2017)
  130. Campbell C, "Risk factors for the development of hepatocellular carcinoma(HCC)in chronic hepatitis B virus(HBV)infection : a systematic review and meta-analysis", J Viral Hepat, 28, pp.493~507 (2021)
  131. Dienstag JL, "Histological outcome during long-term lamivudine therapy", Gastroenterology, 124, pp.105~117 (2003)
  132. Schiff ER, "Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B", Clin Gastroenterol Hepatol, 9, pp.274~276 (2011)
  133. Chang TT, "Longterm entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
  134. Chon YE, "Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis", Am J Gastroenterol, 112, pp.882~891 (2017)
  135. Jeon MY, "Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B", Liver Int, 38, pp.676~686 (2018)
  136. Lee HW, "Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy", Am J Gastroenterol, 109, pp.1241~1249 (2014)
  137. Chon HY, "Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma", Aliment Pharmacol Ther, 53, pp.919~927 (2021)
  138. Kao JH, "Hepatitis B vaccination and prevention of hepatocellular carcinoma", Best Pract Res Clin Gastroenterol, 29, pp.907~917 (2015)
  139. Hung GY, "Changing incidence patterns of hepatocellular carcinoma among age groups in Taiwan", J Hepatol, 63, pp.1390~1396 (2015)
  140. Hsu YC, "Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase(TORCH-B) : a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial", Lancet Infect Dis, 21, pp.823~833 (2021)
  141. Kao JH, "East Asia expert opinion on treatment initiation for chronic hepatitis B", Aliment Pharmacol Ther, 52, pp.1540~1550 (2020)

관련 논문AI추천

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection조순구, Jin-Woo Lee, Jung Hwan Yu, Young-Joo Jin대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제3호Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status김미나, Beom Kyung Kim, Do Young Kim, Jun Yong Park, Kwang-Hyub Han, Sang Hoon Ahn, Seong Gyu Hwang, Seung Up Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제2호Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular CarcinomaDanny Ka-Ho Wong, James Fung, Kwan-Lung Ko, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto, Wai-Pan To거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제5호Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patientsAnlin Ma, Bingqiong Wang, Guofeng Chen, Hongxin Piao, Hong You, Huiguo Ding, Hwai-I Yang, Jialing Zhou, Jidong Jia, Shuyan Chen, Tongtong Meng, Wen Xie, Xiaojuan Ou, Xiaoning Wu, Xiaoqian Xu, Yameng Sun, Yuanyuan Kong대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제3호Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinomaJer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제4호Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?Ho Soo Chun, Minjong Lee대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제3호

이 간행물의 다른 논문 (26건)

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer AssociationHyunchul Rhim, 김경민, Jin Woo Choi, Hee Ho Chu, Jung Suk Oh, In Joon Lee, Dong Hyeon Lee, Byung Chan Lee, Yuri Cho, Han Ah Lee, Dongho Hyun, Hoon Kwon, Kun Yung Kimpp. 521-541KASL clinical practice guidelines for management of autoimmune hepatitis 2022The Korean Association for the Study of the Liver (KASL)pp. 542-592Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversityTakumi Kawaguchi, Tomotake Shirono, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimosepp. 593-604Acute hepatitis C virus infection: clinical update and remaining challengesJia-Horng Kao, Chen-Hua Liupp. 623-642A decade of liver organoids: Advances in disease modelingJunjun Ding, Chun-Fang Yang, Jian-Ying Sheng, Yue Liu, Yun-Shen Chanpp. 643-669
원문 보기